If you have been reading about tetrapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-11. Numbers and descriptions here follow the published literature rather than marketing material.
The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.
Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.
Discussions in the literature often conflate three distinct entities: the pineal extract epithalamin, the isolated tetrapeptide AEDG, and commercial preparations sold under similar names. Reviews citing older Russian-language studies sometimes omit detail on purity, route of administration and control groups, which makes cross-study comparison difficult. Researchers working with the compound generally note the need for independent replication, standardized enzyme assays, and clearer reporting of peptide identity. These caveats are relevant when weighing claims that appear in secondary sources rather than in primary reports.
（TG:@pojiaai）Epitalon is a synthetic linear tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. It emerged from work on epithalamin, a peptide fraction prepared from bovine pineal tissue, and was designed as a short, chemically defined analogue of that extract. Early publications came mainly from Russian laboratories studying pineal peptides and aging-related endpoints. The compound appears in the literature under several spellings, including epithalon and epithalone, which complicates systematic searching. Its small size makes solid-phase assembly and routine analytical characterization straightforward.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not an approved drug | Marketed in most countries as a research chemical |
| Main literature language | Russian and English | Early reports concentrated in Russian journals |
| Typical stated purity | ≥95% by HPLC | Supplier declaration, seldom independently verified |
| Principal studied endpoint | Telomerase activity in vitro | Measured in cultured human cells |
| Reported administration routes | Subcutaneous, intranasal | Described in exploratory use reports |
Stability depends strongly on pH, temperature and the presence of oxygen and trace metals. Cleavage of the backbone proceeds faster under neutral to alkaline conditions, whereas acidic solutions tend to slow that reaction. The aspartate and glutamate side chains can undergo deamidation or imide formation over time, generating closely related impurities. Published stability data specific to epitalon are sparse, so the usable life of a given solution is best regarded as an open question that depends on buffer composition, concentration and storage temperature.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection, frequently near 214 nanometers where the peptide bond absorbs. Mass spectrometry, most often with electrospray ionization, confirms the observed molecular mass and helps separate the intact peptide from truncated or modified forms. Amino acid analysis or tandem mass spectrometry can establish residue order. Purity is commonly quoted as an area percentage, yet such values are method-dependent, and comparisons between laboratories require matching column, gradient and detection wavelength.
Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and its calculated monoisotopic mass is approximately 390.35 daltons. The compound does not occur naturally as a free peptide; it is produced by solid-phase peptide synthesis. Because it contains two acidic residues and no basic residues, the neutral form carries a net negative charge at physiological pH. This charge profile influences how the peptide behaves in solution and during chromatographic analysis.
Laboratory-grade epitalon is typically supplied as a lyophilized powder. Purity is commonly assessed with reverse-phase high-performance liquid chromatography, often paired with mass spectrometry to confirm molecular identity. Amino acid analysis and peptide mapping can provide additional confirmation of sequence. Certificates of analysis for research materials frequently report purity above 95 percent, although the methods behind such figures vary between suppliers. The absence of a pharmacopeial monograph means that no single standardized assay defines the compound, so reported results depend on the analytical protocol chosen.
Storage recommendations center on limiting moisture, heat, and light. The dry powder is generally kept at minus 20 degrees Celsius, and some suppliers recommend minus 80 degrees for long-term archival. Once dissolved, solutions are usually aliquoted and frozen to avoid repeated freeze-thaw cycles, which can promote aggregation or degradation. Aqueous stability depends on pH and concentration, and buffered saline is often preferred over plain water for biological work. Stability data specific to epitalon remain limited, so general peptide-handling practices are applied by analogy rather than from product-specific validation.
The Southern Rhodesians claimed that Butler justified his refusal to give a written promise by saying that binding Whitehall to a document rather than his word would be against the Commonwealth's "spirit of trust"—an argument that Field eventually accepted. "Let's remember the trust you emphasised", Smith warned, according to Field's account wagging his finger at Butler; "if you break that you will live to regret it." Southern Rhodesia attended the conference, which was held at Victoria Falls over a week starting from 28 June 1963, and among other things it was agreed to formally liquidate the Federation at the end of the year. In the House of Commons afterwards, Butler flatly denied suggestions that he had "oiled the wheels" of Federal dissolution with secret promises to the Southern Rhodesians. Field's government was startled by Britain's announcement in October 1963 that Nyasaland would become fully independent on 6 July 1964. While no date was set for Northern Rhodesian statehood, it was generally surmised that it was going to follow shortly thereafter. Smith was promptly sent to London, where he held a round of inconclusive Southern Rhodesian independence talks with the new British Prime Minister, Sir Alec Douglas-Home.
=== Recovery and outcomes === Blepharoplasty is typically performed as an outpatient procedure and may take one to three hours depending on the extent of surgery. Postoperative swelling and bruising are common and generally resolve over several weeks. Supportive measures such as cold compresses and head elevation are often recommended during the early recovery period. Incisions are typically closed with fine sutures, which may be removed within several days in the case of external approaches or may be absorbable depending on the technique used. Suture management and wound care play a role in minimizing scarring and supporting proper healing. Results vary based on patient anatomy and surgical technique, but generally include improvement in eyelid contour, reduction of excess tissue, and a more defined eyelid–cheek junction.
In the DSM-II, stressing the intensity and variability of moods, it was called cyclothymic personality (affective personality). While the term "borderline" was evolving to refer to a distinct category of disorder, psychoanalysts such as Otto Kernberg were using it to refer to a broad spectrum of issues, describing an intermediate level of personality organization between neurosis and psychosis. After standardized criteria were developed by John Gunderson to distinguish it from mood disorders and other Axis I disorders, BPD became a personality disorder diagnosis in 1980 with the publication of the DSM-III. The diagnosis was distinguished from sub-syndromal schizophrenia, which was termed "schizotypal personality disorder". The DSM-IV Axis II Work Group of the American Psychiatric Association finally decided on the name "borderline personality disorder", which is still in use by the DSM-5. However, the term "borderline" has been described as uniquely inadequate for describing the symptoms characteristic of this disorder. Psychodynamic theorists have historically offered the most comprehensive theoretical models of BPD. Gunderson emphasized the patient's fundamental interpersonal hypersensitivity, which he viewed as partially genetic. Kernberg sees the disorder as one involving disturbed object relations, marked by an excess of aggression and use of primitive defenses, such as splitting, projection, and projective identification.
Sources: en.wikipedia.org
== Legal implications == At common law, in general, a myocardial infarction is a disease but may sometimes be an injury. This can create coverage issues in the administration of no-fault insurance schemes such as workers' compensation. In general, a heart attack is not covered; however, it may be a work-related injury if it results, for example, from unusual emotional stress or unusual exertion. In addition, in some jurisdictions, heart attacks had by persons in particular occupations such as police officers may be classified as line-of-duty injuries by statute or policy. In some countries or states, a person having had an MI may be prevented from participating in activity that puts other people's lives at risk, for example driving a car or flying an airplane.
John E. Macor is an American medicinal chemist known for his contributions to drug discovery in neuroscience and other therapeutic areas. He is a co-inventor of four drugs approved by the U.S. Food and Drug Administration (FDA): the migraine treatments eletriptan (Relpax), rimegepant (Nurtec ODT), and zavegepant (Zavzpret), and sparsentan (Filspari), a treatment for IgA nephropathy. In 2014, he was inducted into the Hall of Fame of the American Chemical Society’s Division of Medicinal Chemistry. Macor currently works at Babylon Biosciences, a San Francisco-based startup focused on treatments for Alzheimer's disease.
== Background == The human immune system relies on antibodies; these are specialized proteins produced by B cells in response to the presence of antigens. Antigens are typically foreign molecules that are parts of bacteria, viruses, or other pathogens that trigger an immune response. Antibodies bind to these antigens to neutralize them, block their activity, or mark them for destruction by other immune system cells. The immune system fails to distinguish between self and non-self, a process called immune tolerance. In normal conditions, the immune system is trained to recognize the body's cells or proteins and is labeled as "self" while identifying harmful substances as "non-self". This causes it to produce autoantibodies that target the body's own healthy tissues. Autoantibodies can cause inflammation, tissue damage, and contribute to the progression of various chronic diseases. Some people may inherit genes that increase their risk of developing autoimmune disease, while other triggers such as viral infections or immune system stressors may add to the loss of immune tolerance. When this happens, the immune system starts to recognize some of the body's own proteins as foreign and produces antibodies to fight against them. Anti-U1 RNP antibodies are one example. However, not everyone who inherits genetic risk will develop a disease. Many factors can work together before the immune system begins attacking the body's own tissues.
This suggests that another factor(s) besides the variant Val58Ile protein's structure is involved in its organ/tissue deposition. A second SNP which is also commonly found in Mexicans occurs at codon 172 of the LECT2 gene. This variant is homozygous for a G nucleotide at this codon position and is associated with an increased incidence of LECT2 amyloidosis. A reason for this association has not yet been proposed. It has been found repeatedly that the mere presence of LECT2 amyloid tissue deposits does not necessarily indicate the presence of LECT2 amyloidosis disease. For example, autopsy studies find that up to 3.1% of Hispanics have these deposits in their kidneys but no history of signs or symptoms that could be attributed to LECT2 amyloidosis. This finding suggests that the LECT2 amyloidosis and its ethnic bias reflect multiple poorly understood factors.
Sources: en.wikipedia.org
Applications in the musculoskeletal system include spinal imaging, assessment of joint disease, and soft tissue tumors. MRI techniques can also be used for diagnostic imaging of systemic muscle diseases including genetic muscle diseases. Swallowing movements of the throat and esophagus can cause motion artifacts over the imaged spine. Therefore, a saturation pulse applied over this region can help to avoid these artifacts. Motion artifacts arising due to the pumping of the heart can be reduced by timing the MRI pulse according to heart cycles. Blood vessel flow artifacts can be reduced by applying saturation pulses above and below the region of interest.
== Structure == The structure of the human PLC has been determined using single-particle electron cryo-microscopy (cryo-EM). The PLC, measuring 150 Å by 150 Å and with a total height of 240 Å, is organized around the Transporter associated with Antigen Processing (TAP). It includes molecules such as tapasin, calreticulin, ERp57, and Major Histocompatibility Complex class I (MHC-I), arranged in a pseudo-symmetric pattern.
Acral nevus (melanocytic nevus of acral skin, melanocytic nevus with intraepidermal ascent of cells) Amelanotic blue nevus (hypomelanotic blue nevus) Balloon cell nevus Bannayan–Riley–Ruvalcaba syndrome Becker's nevus (Becker's melanosis, Becker's pigmentary hamartoma, nevoid melanosis, pigmented hairy epidermal nevus) Benign melanocytic nevus (banal nevus, common acquired melanocytic nevus, mole, nevocellular nevus, nevocytic nevus) Blue nevus (blue neuronevus, dermal melanocytoma, nevus bleu) Blue nevus of Jadassohn–Tièche (common blue nevus, nevus ceruleus) Carney complex (LAMB syndrome, NAME syndrome) Cellular blue nevus Centrofacial lentiginosis Congenital melanocytic nevus Deep penetrating nevus Dysplastic nevus (atypical mole, atypical nevus, B-K mole, Clark's nevus, dysplastic melanocytic nevus, nevus with architectural disorder) Dysplastic nevus syndrome (B-K mole syndrome, familial atypical multiple mole–melanoma syndrome, familial melanoma syndrome) Ephelis (freckle) Epithelioid blue nevus Generalized lentiginosis Giant pigmented nevus (bathing trunk nevus, congenital nevomelanocytic nevus, garment nevus, giant hairy nevus, nevus pigmentosus et pilosus) Halo nevus (leukoderma acquisitum centrifugum, perinevoid vitiligo, Sutton nevus) Hori's nevus (acquired bilateral nevus of Ota-like macules) Inherited patterned lentiginosis in black persons Ink spot lentigo (sunburn lentigo) Laugier–Hunziker syndrome Lentigo simplex (simple lentigo) Malignant blue nevus Medium-sized congenital nevocytic nevus Melanoacanthoma Melanocytic tumors of uncertain malignant potential Moynahan syndrome Mucosal lentigines (labial and penile and vulvar melanosis, melanotic macules) Nevus of Ito (nevus fuscoceruleus acromiodeltoideus) Nevus of Ota (congenital melanosis bulbi, melanosis bulborum and aberrant dermal melanocytosis, nevus fuscoceruleus ophthalmomaxillaris, oculodermal melanocytosis, oculomucodermal melanocytosis) Nevus spilus (speckled lentiginous nevus, zosteriform lentiginous nevus) Partial unilateral lentiginosis (segmental lentiginosis) Peutz–Jeghers syndrome Pigmented spindle cell nevus (pigmented spindle cell tumor of Reed, pigmented variant of Spitz nevus) Pseudomelanoma (recurrent melanocytic nevus, recurrent nevus) PUVA lentigines Small-sized congenital nevocytic nevus Spitz nevus (benign juvenile melanoma, epithelioid and spindle cell nevus, Spitz's juvenile melanoma) Solar lentigo (lentigo senilis, liver spot, old age spot, senile freckle)
Sources: en.wikipedia.org
Small studies with human participants have been reported, chiefly in Russian-language journals, but they are limited in size and design. No large randomised controlled trial with published results is available.
The most reproducible biochemical observation comes from cultured cells, where the peptide was reported to raise telomerase activity. Whether this translates into measurable health effects in animals or humans is not established.
It is offered as a research chemical for laboratory use, which places it outside the approval pathways applied to medicines. Buyers should expect documentation to differ between suppliers.
It is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, often abbreviated AEDG. The molecule is linear and contains no modified residues, so it is fully described by its sequence.